Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Autolus Therapeutics (AUTL) Other Operating Expenses: 2017-2025

Historic Other Operating Expenses for Autolus Therapeutics (AUTL) over the last 6 years, with Sep 2025 value amounting to $28.6 million.

  • Autolus Therapeutics' Other Operating Expenses rose 12944.39% to $28.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.5 million, marking a year-over-year decrease of 63.45%. This contributed to the annual value of -$223,000 for FY2024, which is 94.12% up from last year.
  • Autolus Therapeutics' Other Operating Expenses amounted to $28.6 million in Q3 2025, which was up 17.17% from $24.4 million recorded in Q2 2025.
  • Over the past 5 years, Autolus Therapeutics' Other Operating Expenses peaked at $266.9 million during Q4 2023, and registered a low of -$90.8 million during Q3 2023.
  • In the last 3 years, Autolus Therapeutics' Other Operating Expenses had a median value of $205,500 in 2024 and averaged $23.7 million.
  • As far as peak fluctuations go, Autolus Therapeutics' Other Operating Expenses tumbled by 8,532.23% in 2022, and later skyrocketed by 51,933.59% in 2023.
  • Autolus Therapeutics' Other Operating Expenses (Quarterly) stood at -$1.3 million in 2021, then surged by 61.80% to -$515,000 in 2022, then soared by 51,933.59% to $266.9 million in 2023, then tumbled by 95.73% to $11.4 million in 2024, then spiked by 12,944.39% to $28.6 million in 2025.
  • Its Other Operating Expenses was $28.6 million in Q3 2025, compared to $24.4 million in Q2 2025 and -$3,000 in Q1 2025.